Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03562832
Recruitment Status : Recruiting
First Posted : June 20, 2018
Last Update Posted : August 28, 2019
Sponsor:
Collaborators:
Smerud Medical Research International AS
Danish Breast Cancer Cooperative Group
Information provided by (Responsible Party):
Oncology Venture

Brief Summary:

2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells. The PARP inhibitor demonstrated clinical activity in a prior Phase 1 study in a number of solid tumors. 2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2. The molecule is also active in P-glycoprotein expressing cells, suggesting it may overcome some of the PARP inhibitor resistance.

The Phase 2 study is using 2x-121 DRP® biomarker in metastatic breast cancer patients to identify patients likely to respond to and benefit from treatment with 2X-121.


Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Drug: PARP inhibitor 2X-121 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II, Open Label Clinical Study to Investigate Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
Actual Study Start Date : June 20, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : October 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: PARP inhibitor 2X-121
600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
Drug: PARP inhibitor 2X-121
600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients




Primary Outcome Measures :
  1. Anti-tumour efficacy after treatment with 600 mg 2X-121 as single oral agent in a 21-days cycle in mBC patients selected by the 2X-121 DRP [ Time Frame: one year ]
    Overall tumor response according to RECIST


Secondary Outcome Measures :
  1. Progression free survival (PFS) after administration of 2X-121 in patients with mBC [ Time Frame: one year ]
    Timespan

  2. Duration of objective response after administration of 2X-121 in patients with mBC [ Time Frame: one year ]
    Timespan

  3. Overall survival (OS) after administration of 2X-121 in patients with mBC [ Time Frame: one year ]
    Timespan

  4. Performance status (ECOG) [ Time Frame: one year ]
    To evaluate change in patient performance status by ECOG (Eastern Cooperative Oncology Group) Performance Status by a 6-step classification system

  5. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: one year ]
    Adverse Events as assessed by CTCAE v4. to evaluate safety profile after administration of 2X-121 in patients with mBC



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent form.
  • Age 18 years or older.
  • Histologically or cytological documented mBC (independent of hormone receptor, HER2 status and BRCA1 or 2 status) relapsed in 2 or more different prior therapies.
  • Measurable disease by CT scan or MRI.
  • With a drug response prediction (DRP) for 2X-121 with an outcome measured as being in the upper 20% likelihood of response.
  • Prior chemotherapy or hormone therapy for metastatic breast cancer is allowed.
  • Performance status of ECOG <= 1
  • Recovered to Grade 1 or less from prior surgery or from acute toxicities of prior radiotherapy, or from treatment with cytotoxic, hormonal or biologic agents).
  • >= 2 weeks must have elapsed since any prior surgery or therapy with G-CSF and GM-CSF.
  • Patients with intracranial disease must be on stable or decreased level of steroid therapy (e.g. dexamethasone) for at least 7 days prior to baseline MRI. Non-enzymatic inducing ant-epileptic drugs are allowed.
  • Adequate conditions as evidenced by the following clinical laboratory values:

    • Absolute neutrophils count (ANC) >= 1.5 x 10E9/L
    • Haemoglobin is at least 4.6 mmol/L
    • Platelets >= 100 x 10E9 /L
    • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN*
    • Serum bilirubin <= 1.5 ULN
    • Alkaline phosphatase <= 2.5 x ULN*
    • Creatinine <= 1.5 ULN
    • Blood urea within normal limits
    • Creatinine clearance within normal limits. *In case of known liver metastases with ALT and AST <= 5 x ULN and/or alkaline phosphatase <= 5 x ULN. Patients who do not conform to the transaminase and/or alkaline phosphatase inclusion criteria, but who by the PI are considered in good PS and otherwise eligible for inclusion, and where the transaminase and/or alkaline phosphatase levels are considered elevated due to other reasons than deteriorated lever capacity, may be considered for inclusion based on conferred agreement between PI and sponsor.
  • Life expectancy equal or longer than 3 months.
  • Sexually active females of child-producing potential must use adequate contraception (oral contraceptives, intrauterine device or barrier method of contraception) for the study duration and at least six months afterwards.

Exclusion Criteria:

  • - Concurrent chemotherapy, radiotherapy, hormonal therapy, or other investigational drug except non-disease related conditions (e.g. insulin for diabetes) during study period.
  • Other malignancy with exception of curative treated non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to entering the study.
  • Previous treatment with PARP inhibitors
  • Any active infection requiring parenteral or oral antibiotic treatment.
  • Has known HIV positivity.
  • Has known active hepatitis B or C.
  • Has clinical significant (i.e. active) cardiovascular disease:

    • Stroke within <= 6 months prior to day 1
    • Transient ischemic attach (TIA) within <= 6 months prior to day 1
    • Myocardial infarction within <= 6 months prior to day 1
    • Unstable angina
    • New York Hart Association (NYHA) Grade II or greater congestive heart failure (CHF)
    • Serious cardiac arrhythmia requiring medication
  • Mental status is not fit for clinical study or CNS disease including symptomatic epilepsy.
  • Other medications or conditions, including surgery, that in the Investigator's opinion would contraindicate study participation of safety reasons or interfere with the interpretation of study results
  • Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of 2X-121.
  • Requiring immediate palliative treatment of any kind including surgery and/or radiotherapy.
  • Female patients who are pregnant or breast-feeding (pregnancy test with a positive result before study entry)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03562832


Contacts
Layout table for location contacts
Contact: Malgorzata Tuxen, Consultant, MD +45 38683868 malgorzata.tuxen@regionh.dk

Locations
Layout table for location information
Denmark
Herlev and Gentofte Hospital, Herlev Ringvej 75, DK-2730 Herlev Recruiting
Herlev, Denmark, 2730
Contact: Malgorzata Tuxen, Consultant, MD       malgorzata.tuxen@regionh.dk   
Vejle Sygehus Not yet recruiting
Vejle, Denmark, 7100
Contact: Erik Hugger Jakobsen, Consultant, MD    +45 79406015    erik.hugger.jakobsen@rsyd.dk   
Sponsors and Collaborators
Oncology Venture
Smerud Medical Research International AS
Danish Breast Cancer Cooperative Group
Additional Information:
Layout table for additonal information
Responsible Party: Oncology Venture
ClinicalTrials.gov Identifier: NCT03562832    
Other Study ID Numbers: OV-121
SMR-3475 ( Other Identifier: Smerud Medical Research International )
First Posted: June 20, 2018    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Oncology Venture:
PARP inhibitor
Drug Response Prediction (DRP)
Tankyrase 1/2 inhibitor
mRNA biomarker
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents